CVS Health Files 8-K Report
Ticker: CVS · Form: 8-K · Filed: Aug 15, 2025 · CIK: 64803
Sentiment: neutral
Topics: filing, corporate-reporting
Related Tickers: CVS
TL;DR
CVS Health filed a routine 8-K, no major news yet.
AI Summary
On August 11, 2025, CVS Health Corporation filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits. No specific new material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting by CVS Health, providing updates on events and financial exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without any disclosed material events or negative news.
Key Players & Entities
- CVS HEALTH Corp (company) — Registrant
- 0000064803 (company) — Central Index Key
- 05-0494040 (company) — IRS Employer Identification No.
- Delaware (company) — State of incorporation
- 001-01011 (company) — Commission File Number
- August 11, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for CVS Health?
The filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate reporting.
When was the earliest event reported in this filing?
The earliest event reported is August 11, 2025.
What is CVS Health's state of incorporation?
CVS Health's state of incorporation is Delaware.
What is the principal executive office address for CVS Health?
The address is One CVS Drive, Woonsocket, Rhode Island, 02895.
Does this filing disclose any specific new financial results or material events?
Based on the provided excerpt, no specific new financial results or material events are detailed; it appears to be a standard filing.
Filing Stats: 826 words · 3 min read · ~3 pages · Grade level 9.4 · Accepted 2025-08-15 16:10:49
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share CVS New York Stock Exchan
- $750,000,000 — d to issue and sell to the Underwriters $750,000,000 aggregate principal amount of its 5.000
- $1,500,000,000 — nior Notes due 2032 (the "2032 Notes"), $1,500,000,000 aggregate principal amount of its 5.450
- $1,250,000,000 — nior Notes due 2035 (the "2035 Notes"), $1,250,000,000 aggregate principal amount of its 6.200
- $500,000,000 — r Notes due 2055 (the "2055 Notes") and $500,000,000 aggregate principal amount of its 6.250
- $3,958,207,500 — yable by the Company, are approximately $3,958,207,500. A copy of the Underwriting Agreement i
Filing Documents
- d32562d8k.htm (8-K) — 31KB
- d32562dex11.htm (EX-1.1) — 169KB
- d32562dex41.htm (EX-4.1) — 55KB
- d32562dex42.htm (EX-4.2) — 55KB
- d32562dex43.htm (EX-4.3) — 55KB
- d32562dex44.htm (EX-4.4) — 55KB
- d32562dex51.htm (EX-5.1) — 13KB
- g32562g0814233928094.jpg (GRAPHIC) — 2KB
- 0001193125-25-181862.txt ( ) — 647KB
- cvs-20250811.xsd (EX-101.SCH) — 3KB
- cvs-20250811_lab.xml (EX-101.LAB) — 17KB
- cvs-20250811_pre.xml (EX-101.PRE) — 11KB
- d32562d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The exhibits to this Current Report on Form 8-K are as follows: INDEX TO EXHIBITS Exhibit Description 1.1 Underwriting Agreement dated August 11, 2025, among CVS Health Corporation and Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the several Underwriters named in Schedule I thereto. 4.1 Form of the 2032 Note. 4.2 Form of the 2035 Note. 4.3 Form of the 2055 Note. 4.4 Form of the 2065 Note. 5.1 Opinion of Wachtell, Lipton, Rosen & Katz. 23.1 Consent of Wachtell, Lipton, Rosen & Katz (included in Exhibit 5.1). 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CVS HEALTH CORPORATION Date: August 15, 2025 By: /s/ Brian Newman Brian Newman Executive Vice President and Chief Financial Officer